Akebia Therapeutics Inc

NASDAQ: AKBA
$1.33
+$0.01 (+0.8%)
Closing Price on October 4, 2024

AKBA Stock Chart and Intraday Price

AKBA Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 245 FIRST STREET, CAMBRIDGE, MA, US
Fiscal Year End December
Latest Quarter 9/30/2023
Market Cap 322.15M USD
Shares Outstanding 188,389,000
Akebia Therapeutics Inc is a biopharmaceutical company dedicated to developing treatments for kidney diseases. Its main project, Vafseo (vadadustat), targets anemia in chronic kidney disease (CKD) patients, both those undergoing dialysis and those who are not. Additionally, Akebia offers Auryxia, a medication for managing serum phosphorus in dialysis-dependent CKD patients and treating iron deficiency anemia in non-dialysis CKD patients. The company collaborates globally, including with Mitsubishi Tanabe Pharma for vadadustat in Asia. Founded in 2007, Akebia is based in Cambridge, Massachusetts.

AKBA Articles

With Jobless Claims Near 50-Year Low, Analysts Upgrade and Downgrade AMD, Dell, HP and More
Thursday’s additional top analyst upgrades and downgrades included Advanced Micro Devices, Akebia Therapeutics, Dell Technologies, HP, Starwood Property Trust and State Street.
Chris Lange
Published:

Biogen, 3D Systems, Duke Energy, Ford and More of Friday Afternoon's Analyst Calls
The Friday afternoon analyst calls were focused on Biogen, 3D Systems, Duke Energy, Ford, and more.
Chris Lange
Published:

Top Analyst Upgrades and Downgrades: Akebia, Broadcom, DocuSign, Lululemon, NextEra, Overstock.com, Shopify, Wayfair and More
Friday's top analyst calls included Akebia Therapeutics, Broadcom, DocuSign, Lululemon Athletica, NextEra Energy, Overstock.com, Shopify and Wayfair.
Jon C. Ogg
Published: